These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26980019)

  • 1. SOX9 expression predicts relapse of stage II colon cancer patients.
    Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of polycomb group protein B-cell-specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients.
    Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    APMIS; 2016 Jul; 124(7):541-6. PubMed ID: 27102362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of CD11c indicates favorable prognosis in patients with gastric cancer.
    Wang Y; Xu B; Hu WW; Chen LJ; Wu CP; Lu BF; Shen YP; Jiang JT
    World J Gastroenterol; 2015 Aug; 21(31):9403-12. PubMed ID: 26309367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.
    Guo X; Xiong L; Sun T; Peng R; Zou L; Zhu H; Zhang J; Li H; Zhao J
    Diagn Pathol; 2012 Apr; 7():44. PubMed ID: 22515642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
    Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
    Sinicrope FA; Rego RL; Ansell SM; Knutson KL; Foster NR; Sargent DJ
    Gastroenterology; 2009 Oct; 137(4):1270-9. PubMed ID: 19577568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
    Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
    Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.
    Park JS; Chon HJ; Jeung HC; Shin SJ; Rha SY; Ahn JB; Lee KY; Kim NK; Chung HC
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):2051-9. PubMed ID: 27447697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.